For nearly two years, WuXi AppTec, the Chinese contract research giant with extensive ties with U.S. biotech and pharmaceutical companies, operated under cloud, as Congress threatened to restrict its business in this country. That threat has now dissipated, at least for now, and WuXi appears to be flourishing.
In the first nine months of 2025, the company’s revenues in the United States — its largest market — climbed by 31.9% to about $3.1 billion, while the U.S. share of its total sales inched upward. By contrast, sales in China, its second-largest market, were nearly flat.
To many observers, the decision by U.S. lawmakers not to target WuXi as part of a national security crackdown underscores a broader reality: The U.S. biopharma industry is not ready — or willing — to decouple from Chinese partners like WuXi.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
To read the rest of this story subscribe to STAT+.